Affinage

Showing SETD7 — SET9 is a alias.

SETD7

Histone-lysine N-methyltransferase SETD7 · UniProt Q8WTS6

Length
366 aa
Mass
40.7 kDa
Annotated
2026-06-10
100 papers in source corpus 43 papers cited in narrative 41 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 10/10 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SETD7 (SET7/9, KMT7) is a SET-domain protein lysine methyltransferase that controls transcription and signaling by depositing a single methyl mark on histone and, predominantly, non-histone substrates (PMID:11850410, PMID:12540855). Active-site geometry restricts it to mono-methylation: a target lysine inserts into a narrow channel between the substrate and AdoMet binding surfaces, and Tyr-335 acts as the catalytic base that limits product to the mono-methyl state (PMID:12540855, PMID:17517655). Substrate selection follows a defined K/R-S/T/A consensus preceding the target lysine, and methylation is suppressed when adjacent residues are phosphorylated or otherwise modified (PMID:16415881, PMID:21276944). On chromatin, SETD7 monomethylates histone H3K4 to activate transcription by excluding the NuRD deacetylase complex and antagonizing Suv39h1-mediated H3K9 methylation (PMID:11850410), a writer logic it reuses at myogenic promoters through direct interaction with MyoD (PMID:21859860). The dominant biology of SETD7, however, is the methylation of transcription factors and signaling proteins, where individual marks tune substrate stability, DNA binding, partner recruitment, or subcellular localization: it methylates ERα, AR, FXR, Pdx1, and Gli3 to enhance their promoter recruitment and transactivation (PMID:18471979, PMID:20959290, PMID:21273441, PMID:22345554, PMID:25713082, PMID:27146893), while methylation of DNMT1, NF-κB RelA, β-catenin, FoxO3, and SOX2 directs them toward proteasomal degradation (PMID:19282482, PMID:19262565, PMID:26116705, PMID:22820736, PMID:29358331). A recurrent theme is regulation of the Hippo effector YAP, where SETD7 methylates YAP at K494 to enforce cytoplasmic retention, linking it to intestinal progenitor control, Wnt/β-catenin crosstalk, and cardiomyocyte antioxidant gene expression (PMID:23850191, PMID:27046831, PMID:35709329). SETD7 also restrains heterochromatin and DNA-damage responses by methylating SUV39H1, ARTD1/PARP1, and UHRF1 (PMID:23509280, PMID:24088713, PMID:30357346), and it modulates mitosis by dimethylating PLK1 to dampen its kinase activity at kinetochores (PMID:31863092). Beyond catalysis, SETD7 functions as a reader of H3K36 methylation to drive stage-specific transcription during cardiac differentiation, associating with SWI/SNF and NKX2.5 (PMID:29499155). Its own abundance and recruitment are set by SENP3-mediated deSUMOylation and TRIM21-mediated proteasomal degradation (PMID:31141694, PMID:32102992), and the selective inhibitor (R)-PFI-2 phenocopies genetic loss (PMID:25136132). The requirement for SETD7-mediated p53 K372 methylation in the DNA-damage response, originally established in knockout MEFs, was not reproduced in two independent knockout strains (PMID:18280244, PMID:21855806, PMID:21855805).

Mechanistic history

Synthesis pass · year-by-year structured walk · 24 steps
  1. 2002 High

    Established SETD7 as a histone methyltransferase and defined its first transcriptional mechanism, answering what enzymatic activity the protein carried.

    Evidence Biochemical isolation with in vitro HMT assays and cross-inhibition assays against Suv39h1 and G9a

    PMID:11850410

    Open questions at the time
    • Did not determine the relative importance of histone versus non-histone targets in cells
    • Genomic targets of H3K4 monomethylation not mapped
  2. 2003 High

    Explained the structural basis for why SETD7 is exclusively a mono-methylase, answering how product specificity is enforced.

    Evidence High-resolution X-ray crystallography of the ternary SET7/9-H3 peptide-AdoMet complex with solution validation

    PMID:12540855

    Open questions at the time
    • Static structure did not reveal catalytic proton-transfer dynamics
    • Did not address how diverse non-histone substrates are accommodated
  3. 2004 High

    Showed SETD7 methylates a non-histone protein (TAF10) to alter a protein-protein interaction, opening the broader non-histone substrate paradigm.

    Evidence In vitro methylation, affinity pull-down, reporter assays, and TAF10-null complementation with a methylation-deficient mutant

    PMID:15099517

    Open questions at the time
    • Scope of non-histone substrate range still undefined
    • Promoter selectivity mechanism not resolved
  4. 2006 High

    Defined the SETD7 substrate-recognition consensus motif, providing a predictive rule for substrate identification.

    Evidence X-ray crystallography of multiple substrate peptide complexes plus mutagenesis and in vitro methylation assays

    PMID:16415881

    Open questions at the time
    • Motif alone does not predict in vivo methylation given modification-dependent inhibition
    • Cellular relevance of newly identified substrates such as TAF7 not tested in vivo
  5. 2007 Medium

    Identified Tyr-335 as the catalytic base and described the conformational change underpinning mono-methylation, refining the catalytic mechanism.

    Evidence QM/MM molecular dynamics and free-energy simulations correlated with Y305F and Y335F mutant analysis

    PMID:17517655

    Open questions at the time
    • Primarily computational; full kinetic dissection not performed
    • Mechanism inferred from histone substrate may differ for non-histone targets
  6. 2008 High

    Linked SETD7 to receptor and inflammatory transcription factor regulation by methylating ERα and NF-κB to control stability and promoter recruitment.

    Evidence In vitro methylation, crystallography of the SET7-ER complex, Co-IP, ChIP, and siRNA knockdown in monocytes

    PMID:18471979 PMID:18650421

    Open questions at the time
    • Whether ERα stabilization and NF-κB coactivation generalize across cell types unresolved
    • Interplay with other ERα/NF-κB modifications not mapped
  7. 2008 High

    Reported that SETD7 methylates p53 at K372 and that this is required for Tip60 binding, p53 acetylation, and tumor suppression — a defining proposed in vivo role.

    Evidence Set7/9 knockout mouse MEFs, DNA damage assays, Tip60-p53 Co-IP, and transformation assays

    PMID:18280244

    Open questions at the time
    • Subsequently contradicted by independent knockout strains
    • Strain background and assay conditions differed from later studies
  8. 2009 High

    Extended SETD7 control to DNA methylation machinery and NF-κB turnover by methylating DNMT1 and RelA to trigger their proteasomal degradation, establishing methylation as a degradation signal.

    Evidence Co-IP, in vitro methylation, mass spectrometry site mapping, proteasome inhibitor and knockdown experiments

    PMID:19262565 PMID:19282482

    Open questions at the time
    • E3 ligases coupling these methylation marks to degradation not identified
    • Cell-cycle coupling of DNMT1 turnover only partially characterized
  9. 2010 High

    Showed SETD7 methylates signaling and viral substrates (AR, HIV-1 Tat) with opposite functional consequences (activation), broadening its regulatory repertoire including RNA-associated functions.

    Evidence In vitro methylation, ChIP, TAR RNA binding assays, and reporter assays with methylation-deficient mutants

    PMID:20227666 PMID:20959290 PMID:21273441

    Open questions at the time
    • Mechanism by which a single mark activates AR yet destabilizes other substrates not unified
    • Physiological role of Tat methylation in viral latency not established
  10. 2011 High

    Two independent knockout strains found SETD7 dispensable for the p53 DNA-damage response, directly challenging the 2008 model and exposing context dependence of non-histone methylation.

    Evidence Two independent Set7/9 knockout mouse strains with comprehensive DNA-damage phenotyping and p53 acetylation analysis

    PMID:21855805 PMID:21855806

    Open questions at the time
    • Source of discrepancy with the original study unresolved
    • Does not exclude tissue- or stress-specific p53 regulation
  11. 2011 Medium

    Defined an indirect p53 regulatory axis and systematic substrate expansion, showing SETD7 can act through SIRT1 sequestration and methylate numerous additional proteins under modification-dependent constraints.

    Evidence Reciprocal Co-IP for SIRT1, peptide-array screening with in vitro/in vivo validation of nine non-histone substrates, and FoxO3 MS site mapping

    PMID:21245319 PMID:21276944 PMID:22820736

    Open questions at the time
    • Many array-identified substrates lack functional follow-up
    • In vivo relevance of SIRT1 and FoxO3 effects from single labs
  12. 2012 High

    Connected SETD7 to heterochromatin integrity and developmental signaling by methylating SUV39H1, FXR, and the Hippo effector YAP, establishing YAP cytoplasmic retention as a key in vivo function.

    Evidence Mass spectrometry, in vitro methylation, micrococcal nuclease assays, EMSA/reporter assays, and a Set7 knockout intestinal progenitor model

    PMID:22345554 PMID:23509280 PMID:23850191

    Open questions at the time
    • How SETD7 balances chromatin-relaxing versus signaling roles in vivo unclear
    • Upstream signals directing YAP methylation not defined
  13. 2013 High

    Revealed SETD7 roles in DNA-damage chromatin responses and TGF-β/fibrosis control by methylating ARTD1/PARP1 and Smad7, with the latter coupling methylation to Arkadia-dependent degradation in vivo.

    Evidence In vitro methylation, laser-induced damage recruitment imaging, ubiquitination assays, and a Set9 knockout lung-fibrosis mouse model

    PMID:24088713 PMID:27292644

    Open questions at the time
    • Direct contribution of ARTD1 methylation to repair outcomes not quantified
    • Pharmacological translation of the fibrosis finding untested in the timeline
  14. 2014 High

    Delivered a potent selective chemical probe ((R)-PFI-2) that occupies the substrate groove and phenocopies genetic loss, enabling acute interrogation of SETD7 function.

    Evidence Ki determination, crystallography of the inhibitor complex, chemoproteomics, and cell-based YAP localization assays

    PMID:25136132

    Open questions at the time
    • Probe does not distinguish individual substrate contributions
    • Off-target methyltransferase activity in complex tissues not exhaustively excluded
  15. 2014 Medium

    Implicated SETD7 in cell-cycle and survival transcription programs through E2F1 coactivation and a proposed Mdm2 interaction, linking it to genotoxic stress responses.

    Evidence Co-IP, ChIP, gene expression and G1/S progression assays across cancer cell lines

    PMID:25124555 PMID:26317544

    Open questions at the time
    • Mdm2 regulation rests on a single low-confidence Co-IP/correlation study without mechanistic depth
    • Direct versus indirect histone effects at E2F1 promoters not separated
  16. 2015 High

    Expanded SETD7 control to metabolic, hypoxic, and developmental transcription factors (Pdx1, HIF-1α/2α, Gli3, β-catenin) with marks driving either activation, repression, or GSK-3β-coupled degradation.

    Evidence In vitro methylation with MS/mutagenesis, ChIP at HREs, half-life assays, and conditional/whole-body knockout phenotypes

    PMID:25713082 PMID:25897119 PMID:26116705 PMID:27146893

    Open questions at the time
    • Why the same enzyme activates some factors and degrades others remains mechanistically unexplained
    • Tissue specificity of these competing outcomes not systematically tested
  17. 2016 High

    Integrated SETD7 into Wnt-Hippo crosstalk and additional transcription-factor regulation, showing YAP methylation gates β-catenin nuclear accumulation and tumorigenesis while YY1 methylation tunes its DNA binding.

    Evidence SETD7 knockout intestinal tumor/regeneration model, YAP-AXIN1-β-catenin complex Co-IP, EMSA, and ChIP

    PMID:26902152 PMID:27046831

    Open questions at the time
    • Stoichiometry and dynamics of the YAP-AXIN1-β-catenin-SETD7 complex unresolved
    • YY1 regulation from a single lab
  18. 2018 High

    Established a catalysis-independent reader function and additional stability control, with SETD7 binding H3K36me to drive cardiac differentiation and methylating SOX2 within a writer-eraser-reader module.

    Evidence ChIP-seq, Co-IP with SWI/SNF and NKX2.5, enzyme-dead mutant analysis, and SOX2 stability assays with LSD1/PHF20L1 knockdown

    PMID:29358331 PMID:29499155

    Open questions at the time
    • Structural basis of H3K36me reading not defined
    • Generality of the catalysis-independent role beyond cardiac lineage untested
  19. 2018 Medium

    Identified Rpl29 K5 as a SETD7-exclusive mark and a cellular biomarker of enzyme activity, providing a tool to monitor inhibition.

    Evidence In vitro methylation, methylation-specific antibody, subcellular fractionation, and (R)-PFI-2 response

    PMID:29959229

    Open questions at the time
    • Functional consequence of Rpl29 methylation limited to localization, with no effect on translation
    • Single lab
  20. 2019 Medium

    Defined how SETD7 activity is positioned and the breadth of its DNA-repair and chromatin roles, showing SENP3 deSUMOylation recruits it to muscle gene loci and that it methylates UHRF1 to promote homologous recombination.

    Evidence Co-IP, deSUMOylation and polyubiquitination assays, ChIP, phosphorylation-mutant analysis, and HR assays

    PMID:30357346 PMID:31141694

    Open questions at the time
    • How SUMOylation status mechanistically gates SETD7 catalysis unclear
    • UHRF1-PCNA repair axis from a single lab
  21. 2020 Medium

    Showed SETD7 regulates mitosis directly by dimethylating PLK1 to dampen kinase activity at kinetochores, expanding its reach beyond transcription.

    Evidence In vitro methylation, K191 mutagenesis, kinase activity assays, and kinetochore-microtubule attachment/mitosis assays with inhibitor

    PMID:31863092

    Open questions at the time
    • This is a dimethylation event, atypical for the canonical mono-methylase, and structural basis is unexplained
    • Single lab
  22. 2016 Medium

    Identified TRIM21 as a proteasomal negative regulator of SETD7, defining how the enzyme's own abundance is controlled in cancer contexts.

    Evidence Mass spectrometry, Co-IP, GST pulldown, ubiquitination assays, and ChIP-seq with xenograft analysis

    PMID:32102992

    Open questions at the time
    • Signals triggering TRIM21-mediated SETD7 degradation not defined
    • Single lab
  23. 2021 Medium

    Linked SETD7 to neurodegeneration-associated Tau modification, with methylation at K132 priming K130 and correlating with pathology stage.

    Evidence Mass spectrometry in human AD brain, methylation-specific antibodies, knockdown/inhibitor studies, and subcellular fractionation

    PMID:34215303

    Open questions at the time
    • Causal contribution of Tau methylation to pathology not established
    • Single lab
  24. 2023 High

    Demonstrated a translational cardioprotective role, with SETD7-mediated YAP methylation impairing antioxidant gene expression during energy deprivation and (R)-PFI-2 preventing ischemia/reperfusion injury.

    Evidence Cardiomyocyte energy-deprivation culture, SETD7 knockout I/R mouse model, pharmacological inhibition, and YAP localization/mtROS readouts

    PMID:35709329

    Open questions at the time
    • Whether benefit derives solely from YAP versus other cardiac substrates not isolated
    • Long-term safety of SETD7 inhibition not addressed

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved what governs whether a given SETD7 methylation event stabilizes versus degrades a substrate, or activates versus represses transcription, and how catalytic versus reader functions are partitioned across tissues.
  • No unifying rule predicting activating versus degradative outcomes
  • Endogenous substrate priority and stoichiometry largely unquantified
  • Reader (H3K36me) versus writer contributions separated only in cardiac differentiation

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 8 GO:0140096 catalytic activity, acting on a protein 8 GO:0042393 histone binding 3 GO:0098772 molecular function regulator activity 3 GO:0003723 RNA binding 1
Localization
GO:0005634 nucleus 4 GO:0005829 cytosol 2
Pathway
R-HSA-162582 Signal Transduction 7 R-HSA-74160 Gene expression (Transcription) 6 R-HSA-1266738 Developmental Biology 4 R-HSA-392499 Metabolism of proteins 4 R-HSA-73894 DNA Repair 3 R-HSA-1640170 Cell Cycle 2 R-HSA-168256 Immune System 2
Partners
DNMT1MYODRELASENP3SIRT1SUV39H1TRIM21YAP1
Complex memberships
YAP-AXIN1-β-catenin complex

Evidence

Reading pass · 41 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2002 Set9 (SETD7) was isolated from human cells and shown to specifically monomethylate lysine 4 of histone H3 (H3-K4). This methylation precludes association of the NuRD histone deacetylase complex with the H3 tail, and also impairs Suv39h1-mediated methylation at H3-K9, thereby promoting transcription activation. Biochemical isolation, in vitro histone methyltransferase assay, histone tail binding assay, cross-inhibition assay with Suv39h1 and G9a Genes & development High 11850410
2003 Crystal structure of a ternary complex of human SET7/9 with a histone H3 peptide and cofactor (AdoMet) revealed that the peptide substrate and cofactor bind on opposite surfaces of the enzyme, the target lysine inserts its side chain into a narrow channel connecting the two surfaces, and SET7/9 is exclusively a mono-methylase due to active-site geometry. High-resolution X-ray crystallography of ternary complex; solution studies confirming mono-methylase activity Nature High 12540855
2004 SET9 (SETD7) monomethylates the TBP-associated factor TAF10 at a single lysine in its histone-fold domain (loop 2 region), and this methylation increases TAF10 affinity for RNA polymerase II, potentiating transcription of a subset of TAF10-dependent genes in a promoter-specific manner. In vitro methyltransferase assay, affinity pull-down, reporter assays, TAF10-null cell complementation with methylation-deficient mutant Molecular cell High 15099517
2006 Crystal structures of SET7/9 bound to TAF10 and other substrate peptides revealed that the enzyme recognizes a conserved K/R-S/T/A motif preceding the target lysine, and has preference for aspartates/asparagines C-terminal to the target lysine, defining the substrate-specificity consensus motif. TAF7 was identified as a novel substrate (methylated at Lys5 in vitro) using this motif. X-ray crystallography, substrate peptide mutagenesis, in vitro methyltransferase assays with multiple substrates Nature structural & molecular biology High 16415881
2007 QM/MM molecular dynamics simulations of SET7/9 identified Tyr-335 as the general base for deprotonation of the methylated lysine after AdoHcy dissociation, and showed that conformational changes bring Y335 to the target lysine for proton abstraction, explaining mono-methylase product specificity. Y305F and Y335F mutants were analyzed to support the mechanism. Quantum mechanical/molecular mechanical (QM/MM) molecular dynamics and free-energy simulations; mutant analysis (Y305F, Y335F) Proceedings of the National Academy of Sciences of the United States of America Medium 17517655
2008 SETD7 directly methylates estrogen receptor alpha (ERα) at lysine 302. SET7-mediated K302 methylation stabilizes ERα protein and is required for efficient recruitment of ERα to its target gene promoters and their transactivation. A breast cancer-associated mutation K303R alters K302 methylation in vitro and in vivo. Crystal structure of the SET7-ER peptide complex revealed the molecular basis of recognition. In vitro methyltransferase assay, X-ray crystallography of SET7-ER peptide complex, Co-IP, ChIP, mutagenesis, K303R cancer mutation analysis Molecular cell High 18471979
2008 SET7/9 acts as a novel coactivator of NF-κB. SET7/9 knockdown in monocytes inhibits TNF-α-induced H3K4 methylation at NF-κB target gene promoters, reduces NF-κB p65 recruitment to those promoters, and attenuates inflammatory gene expression and monocyte adhesion. siRNA knockdown, ChIP, gene expression analysis (microarray), monocyte adhesion assay The Journal of biological chemistry Medium 18650421
2008 Set7/9 methylates p53 at K369 (mouse)/K372 (human) in vivo. Cells from Set7/9 knockout mice fail to methylate p53 K369, cannot induce p53 downstream targets upon DNA damage, and are predisposed to oncogenic transformation. Mechanistically, Set7/9-mediated p53 methylation is required for binding of the acetyltransferase Tip60 to p53 and for subsequent p53 acetylation. Set7/9 knockout mouse generation, MEF-based DNA damage assays, Co-IP (Tip60-p53), p53 acetylation analysis, transformation assays Molecular cell High 18280244
2009 SET7 directly interacts with DNMT1, colocalizes with it, and specifically monomethylates DNMT1 at Lys-142. This methylation promotes proteasome-mediated DNMT1 degradation, peaking during S and G2 phases. SET7 overexpression decreases DNMT1 levels; SET7 siRNA knockdown stabilizes DNMT1. Co-IP, colocalization (immunofluorescence), in vitro methyltransferase assay, proteasome inhibitor experiments, siRNA KD, SET7 overexpression Proceedings of the National Academy of Sciences of the United States of America High 19282482
2009 Set9 (SETD7) physically associates with the RelA subunit of NF-κB and monomethylates RelA at lysine residues 314 and 315 in vitro and in vivo. This methylation inhibits NF-κB action by inducing proteasome-mediated degradation of promoter-associated RelA, limiting the duration of NF-κB target gene expression. Co-IP, in vitro methyltransferase assay, mutational analysis, mass spectrometry, siRNA KD, reporter assays The EMBO journal High 19262565
2010 Set7/9 (KMT7) monomethylates lysine 51 in the RNA-binding domain of HIV-1 Tat. Set7/9 associates with the HIV promoter in vivo, binds TAR RNA by itself and in complex with Tat and P-TEFb. Knockdown of Set7/9 suppresses Tat transactivation in a methylation-dependent manner (K51A Tat is refractory to Set7/9 KD). In vitro methyltransferase assay, ChIP, RNA binding assay (TAR RNA), siRNA KD, luciferase reporter assay with K51A mutant Cell host & microbe High 20227666
2010 SETD7 directly methylates and regulates the androgen receptor (AR). SET9 methylates AR at lysine 632 (also reported as K630 in a parallel study), which is necessary for enhancing AR transcriptional activity by facilitating inter-domain N-C communication and recruitment to androgen-target gene promoters. In vitro methyltransferase assay, Co-IP, ChIP, mutagenesis (K632A), N-C interaction assay Nucleic acids research High 20959290 21273441
2011 Set7/9 interacts with SIRT1 both in vitro and in vivo. Upon DNA damage, Set7/9-SIRT1 interaction is enhanced, suppressing SIRT1-p53 interaction and abrogating SIRT1-mediated p53 deacetylation, thereby promoting p53-mediated transactivation. This regulation operates in addition to direct p53 methylation. Co-IP (in vitro and in vivo), p53 acetylation analysis, SIRT1 methylation analysis, reporter assays, DNA damage response assays Proceedings of the National Academy of Sciences of the United States of America Medium 21245319
2011 Two independent Set7/9 knockout mouse strains showed that Set7/9 is dispensable for p53-dependent cell cycle arrest, apoptosis, and p53 acetylation following DNA damage or oncogene activation in vivo, contradicting the earlier finding (PMID:18280244) that p53 methylation by Set7/9 is required for p53 activation. Independent Set7/9 knockout mouse strain, DNA damage assays (irradiation, genotoxic agents), p53 target gene expression, p53 acetylation analysis Molecular cell High 21855805 21855806
2011 Set7 directly interacts with MyoD and promotes skeletal muscle differentiation. Set7 knockdown or dominant-negative expression impairs myoblast differentiation with decreased H3K4me1, reduced expression of myocyte enhancer factor 2 and contractile proteins, and myofibril assembly defects. Set7 activates muscle genes by precluding Suv39h1-mediated H3K9 methylation on myogenic gene promoters. Co-IP (Set7-MyoD), siRNA KD, dominant-negative overexpression, ChIP (H3K4me1, H3K9me), differentiation assays The Journal of cell biology Medium 21859860
2011 Set9 directly methylates FoxO3 at lysine 271 (identified by tandem mass spectrometry and methyl-specific antibody). Set9-mediated FoxO3 methylation decreases FoxO3 protein stability while moderately increasing its transcriptional activity. In vitro methyltransferase assay, tandem mass spectrometry, methyl-specific antibody, protein stability assay Aging Medium 22820736
2011 SET7/9 can methylate multiple new peptide substrates from human proteins. Confirmed methylation of nine nonhistone proteins (AKA6, CENPC1, MeCP2, MINT, PPARBP, ZDH8, Cullin1, IRF1, TTK) and H2A and H2B in vitro and in vivo. Phosphorylation of substrate proteins adjacent to the target lysine inhibits SET7/9 methylation. MINT protein can be dimethylated by SET7/9 showing context-dependent product specificity. Peptide array methylation, in vitro methyltransferase assays with protein domains, in vivo methylation validation with antibodies Chemistry & biology Medium 21276944
2012 Set7 (Setd7) monomethylates YAP at lysine 494. This methylation is critical for cytoplasmic retention of YAP. Set7 knockout mice have a larger intestinal progenitor compartment with increased YAP target gene expression, placing Set7-mediated YAP methylation as a regulatory checkpoint in the Hippo pathway. Set7 knockout mouse model, intestinal progenitor analysis, in vitro methyltransferase assay, YAP subcellular localization studies, YAP target gene expression Developmental cell High 23850191
2012 SET7/9 directly methylates SUV39H1 at lysines 105 and 123 (identified by mass spectrometry and methyl-specific antibodies). Methylation dramatically down-regulates SUV39H1 methyltransferase activity, leading to decreased H3K9 trimethylation in heterochromatin, heterochromatin relaxation (increased Sat2 and α-Sat expression), and genome instability in response to DNA damage. Co-IP, GST pulldown, in vitro methyltransferase assay, mass spectrometry, methyl-specific antibody, micrococcal nuclease sensitivity assay, immunofluorescence Proceedings of the National Academy of Sciences of the United States of America High 23509280
2012 SET7/9 directly methylates the farnesoid X receptor (FXR) at lysine 206 in vivo and in vitro. Methylation enhances FXR/RXRα binding to the FXRE and potentiates transactivation of FXR target genes (SHP, BSEP). Methylation-deficient K206R mutant FXR shows impaired transactivation; SET7/9 methyltransferase-dead mutant is also inactive. In vitro methyltransferase assay, Co-IP, GST pulldown, mammalian two-hybrid, EMSA, luciferase reporter assay, K206R mutagenesis, siRNA KD American journal of physiology. Gastrointestinal and liver physiology High 22345554
2012 SET7/9 methylates histone H1.4 at multiple lysine residues (K121, K129, K159, K171, K177, K192) in KAK motifs of the C-terminal domain. ADP-ribosylation of H3 by ARTD1 prevents H3 methylation by SET7/9 but allows subsequent SET7/9 methylation of H1. H1 and H3 compete for SET7/9-dependent methylation, revealing substrate competition as a regulatory mechanism. In vitro methyltransferase assay with isolated histones, mass spectrometry identification of methylation sites, competition assays Epigenetics & chromatin Medium 23289424
2013 SET7/9 directly methylates ARTD1 (PARP1) at K508 in vitro and in vivo. ARTD1 methylation by SET7/9 enhances poly-ADP-ribose (PAR) synthesis upon oxidative stress in vivo, and promotes ARTD1 recruitment to sites of laser-induced DNA damage in a SET7/9-dependent manner. ARTD1 auto-modification inhibits its methylation by SET7/9. In vitro methyltransferase assay, in vivo methylation detection, laser irradiation/PAR formation assay, live-cell imaging of ARTD1 recruitment Open biology Medium 24088713
2013 Negative regulation of TGF-β signaling: Set9 methylates Smad7 (an inhibitory TGF-β effector), promoting Smad7 interaction with the E3 ligase Arkadia and subsequent ubiquitination-dependent degradation of Smad7. Set9 depletion or pharmacological inhibition elevates Smad7 levels and inhibits TGF-β-dependent extracellular matrix gene expression. Set9-deficient mice show severely compromised lung fibrosis. In vitro methyltransferase assay, Co-IP (Smad7-Arkadia), ubiquitination assay, Set9 KO mouse model of pulmonary fibrosis (bleomycin/Ad-TGF-β), siRNA and pharmacological inhibitor studies Cell reports High 27292644
2014 (R)-PFI-2 was identified as a potent (Ki = 0.33 nM), selective, cofactor-dependent, substrate-competitive inhibitor of SETD7. Crystal structure showed it occupies the substrate peptide binding groove including the lysine-binding channel and contacts the methyl group of SAM. In murine embryonic fibroblasts, (R)-PFI-2 phenocopied Setd7 deficiency on Hippo pathway signaling via YAP modulation; in confluent MCF7 cells it rapidly altered YAP localization. Biochemical inhibitor characterization (Ki determination), X-ray crystallography, chemoproteomics (biotinylated probe competition), cell-based YAP localization assay Proceedings of the National Academy of Sciences of the United States of America High 25136132
2014 Set7/9 physically interacts with Mdm2 and regulates expression of Mdm2 at the transcriptional level, affecting the DNA damage response. Multiple cancer cell lines with inverse expression of Set7/9 and Mdm2 show diminished survival in response to genotoxic stress. Co-IP, gene expression analysis, cell viability assays under genotoxic stress, bioinformatics Oncotarget Low 26317544
2014 Set7/9 is a critical co-activator of E2F1-dependent transcription in response to DNA damage. Set7/9 indirectly modulates histone modifications at E2F1-dependent gene promoters, promotes CCNE1 expression (proliferation), and represses TP73 gene expression (anti-apoptotic). Cell cycle progression through G1/S checkpoint depends on threshold expression of both E2F1 and Set7/9. Co-IP, ChIP, gene expression analysis, cell biology assays (G1/S progression), bioinformatics across lung tumor cell lines Cell death and differentiation Medium 25124555
2015 Set7 methylates HIF-1α at lysine 32 and HIF-2α at lysine K29, inhibiting HIF-α transcriptional activity by impairing occupancy of HIF-α on hypoxia response elements of target gene promoters. Set7-null fibroblasts and Set7 KD/inhibited cells show upregulated HIF target genes and increased glucose uptake. In vitro methyltransferase assay, ChIP (HIF-α at HRE), Set7 KO fibroblasts, shRNA KD, Set7 inhibitor treatment, glucose uptake assay Nucleic acids research Medium 25897119
2015 Set7 monomethylates Gli3 full-length (but not truncated form) at K436 and K595. Methylation at K436 increases Gli3 stability and methylation at K595 increases Gli3 DNA binding ability, together enhancing Shh signaling activation and contributing to tumor growth/metastasis in non-small cell lung cancer. In vitro methyltransferase assay, mutagenesis (K436A, K595A), protein stability assay, DNA binding assay, Shh target gene expression, in vitro/in vivo tumor assays eLife Medium 27146893
2015 Set7/9 methylates the transcription factor Pdx1 at K123 and K131 (identified by mass spectrometry and mutagenesis of purified proteins). K131 methylation (but not K123) is required for transcriptional augmentation by Set7/9. Conditional deletion of Set7/9 in β cells causes glucose intolerance and impaired glucose-stimulated insulin secretion with reduced Pdx1 target gene expression. In vitro methyltransferase assay, mass spectrometry, mutagenesis, luciferase reporter assay, conditional knockout mouse (Set(Δ)β), islet glucose-stimulated insulin secretion assay The Journal of biological chemistry High 25713082
2015 SET7/9 directly methylates β-catenin at lysine 180 (identified by mutagenesis and mass spectrometry). Methylated β-catenin is recognized by GSK-3β for degradation. K180R mutant β-catenin has a longer half-life. SET7/9 depletion or K180R mutation enhances Wnt/β-catenin target gene expression and promotes cancer cell growth. Co-IP, in vitro methyltransferase assay, mutagenesis (K180R), mass spectrometry, protein half-life assay, luciferase reporter assay FASEB journal High 26116705
2016 SETD7-mediated methylation of YAP (K494) facilitates Wnt-induced nuclear accumulation of β-catenin. SETD7 is part of a complex containing YAP, AXIN1, and β-catenin. SETD7 is required for Wnt-driven intestinal tumorigenesis and regeneration, linking the Wnt/β-catenin and Hippo/YAP pathways. SETD7 KO mouse model (intestinal tumorigenesis/regeneration), Co-IP complex analysis (YAP-AXIN1-β-catenin-SETD7), β-catenin nuclear localization assay Developmental cell High 27046831
2016 SET7/9 methylates transcription factor YY1 at two lysine residues, K173 and K411. This methylation regulates YY1 DNA-binding activity in vitro and at specific genomic loci in cells, affecting YY1-regulated gene transcription and cell proliferation. In vitro methyltransferase assay, mutagenesis, EMSA (DNA binding), ChIP, luciferase reporter assay, cell proliferation assay Scientific reports Medium 26902152
2018 SETD7 controls cardiac differentiation by reading H3K36 marks independently of its enzymatic activity. During mesodermal formation, SETD7 associates with SWI/SNF chromatin-remodeling factors; in cardiac progenitors it associates with NKX2.5. SETD7 binds methylated H3K36 in gene bodies of target genes to facilitate RNA Pol II-dependent transcription. ChIP-seq, Co-IP (SETD7 with SWI/SNF and NKX2.5), enzymatic activity mutant analysis, H3K36me binding assay, differentiation assays from hPSCs Cell stem cell High 29499155
2018 SET7 methylates SOX2 at K119 (mouse)/K117 (human) and K42, triggering ubiquitin-dependent SOX2 proteolysis. LSD1 demethylase removes methyl groups from both sites preventing degradation, while PHF20L1 binds monomethylated K42 and K117 to protect SOX2 from proteolysis. SET7/LSD1/PHF20L1 dynamically regulate SOX2 stability in pluripotent stem cells. In vitro methyltransferase assay, methylation-specific antibody, Co-IP, siRNA KD (LSD1, PHF20L1), protein stability assay, SET7 inactivation The Journal of biological chemistry Medium 29358331
2018 Rpl29 lysine 5 (Rpl29K5) is methylated exclusively by Set7/9 and can be demethylated by Lsd1. Rpl29 methylation has no effect on global protein synthesis but affects Rpl29 subcellular localization. Rpl29K5 methylation was validated as a specific cellular biomarker for Set7/9 activity, responsive to (R)-PFI-2 inhibitor treatment. In vitro methyltransferase assay (substrate identification), methylation-specific antibody, subcellular fractionation, Set7/9 inhibitor treatment, global translation assay The Journal of biological chemistry Medium 29959229
2019 UHRF1 is methylated by SET7 and demethylated by LSD1. UHRF1 phosphorylation in S phase is a prerequisite for its interaction with SET7. SET7-mediated UHRF1 methylation catalyzes polyubiquitin chain conjugation to PCNA and promotes homologous recombination for DNA double-strand break repair. UHRF1 methylation is induced in response to DNA damage. In vitro methyltransferase assay, Co-IP, phosphorylation mutant analysis, polyubiquitination assay (PCNA), homologous recombination assay, cell viability assay Nucleic acids research Medium 30357346
2019 SUMO-specific isopeptidase SENP3 associates with SETD7 and deSUMOylates it. By recruiting SETD7 to the MyHC-II gene locus, SENP3 promotes SETD7 association with active RNA polymerase II and precludes opposing Suv39h1 activity. SENP3 is degraded in cachexia, impairing this SENP3-SETD7 regulatory axis, resulting in disrupted MyHC-II expression and disorganized sarcomeres. Co-IP (SENP3-SETD7), deSUMOylation assay, ChIP (SETD7 and Pol II at MyHC-II), SENP3 KD functional assay, cachexia model Cell reports Medium 31141694
2020 SETD7 methylates PLK1 at K191 (dimethylation), tuning down PLK1 kinase activity by limiting ATP utilization at kinetochores during early mitosis. Non-methylatable PLK1 K191 mutant or chemical inhibition of SETD7 causes mitotic arrest due to destabilized kinetochore-microtubule attachments, revealing that SETD7-mediated PLK1 methylation promotes dynamic kinetochore-microtubule attachments for accurate error correction. In vitro methyltransferase assay, mutagenesis (K191), PLK1 kinase activity assay, kinetochore-microtubule attachment assay, SETD7 inhibitor treatment, mitosis assay Journal of molecular cell biology Medium 31863092
2021 SETD7 methylates Tau at K132, an event that facilitates subsequent methylation at K130. Methylated Tau (identified by mass spectrometry in human AD brain) preferentially localizes to cell soma and nuclear fractions (absent from neurites) in hiPSC-derived neurons and mouse brain, and methylated Tau levels increase with Tau pathology stage. Mass spectrometry (human AD brain), methylation-specific antibody development, knockdown and inhibitor studies, subcellular fractionation, proteomics Molecular neurodegeneration Medium 34215303
2023 SETD7 methylates the Hippo pathway effector YAP upon energy deprivation in cardiomyocytes, leading to YAP cytosolic retention and impaired transcription of antioxidant genes MnSOD and CAT. This impairment causes mitochondrial ROS accumulation, organelle swelling, and apoptosis. Pharmacological inhibition of SETD7 by (R)-PFI-2 restores YAP nuclear localization and prevents myocardial ischemia/reperfusion injury in mice. NRVM culture (energy deprivation), SETD7 KO mouse I/R injury model, (R)-PFI-2 pharmacological inhibition, YAP localization assay, MnSOD/CAT expression, mtROS measurement, LV function assay Cardiovascular research High 35709329
2016 TRIM21 physically associates with SETD7 and functions as a major negative regulator upstream of SETD7 through a proteasome-dependent ubiquitination mechanism, leading to SETD7 degradation. SETD7 promotes breast cancer malignant processes via activation of RUNX2. Mass spectrometry, Co-IP, GST pulldown, ubiquitination assay, ChIP-seq, ChIP, cell functional assays, xenograft model Cell death & disease Medium 32102992

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2002 Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes & development 454 11850410
2003 Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature 308 12540855
2008 Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-dependent inflammatory genes. Relevance to diabetes and inflammation. The Journal of biological chemistry 293 18650421
2012 PR-Set7 and H4K20me1: at the crossroads of genome integrity, cell cycle, chromosome condensation, and transcription. Genes & development 278 22345514
2009 Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America 256 19282482
2008 Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Molecular cell 251 18471979
2004 Gene-specific modulation of TAF10 function by SET9-mediated methylation. Molecular cell 223 15099517
2010 Regulation of the histone H4 monomethylase PR-Set7 by CRL4(Cdt2)-mediated PCNA-dependent degradation during DNA damage. Molecular cell 204 21035370
2008 Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Molecular cell 187 18280244
2009 Negative regulation of NF-kappaB action by Set9-mediated lysine methylation of the RelA subunit. The EMBO journal 186 19262565
2014 (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells. Proceedings of the National Academy of Sciences of the United States of America 156 25136132
2013 Control of the hippo pathway by Set7-dependent methylation of Yap. Developmental cell 147 23850191
2006 Structural basis for the methylation site specificity of SET7/9. Nature structural & molecular biology 142 16415881
2011 Specificity analysis-based identification of new methylation targets of the SET7/9 protein lysine methyltransferase. Chemistry & biology 141 21276944
2007 PR-Set7-dependent lysine methylation ensures genome replication and stability through S phase. The Journal of cell biology 139 18158331
2012 Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circulation research 134 22403242
2020 METTL3/YTHDF2 m6 A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer. Journal of cellular and molecular medicine 126 32126149
2011 Methyltransferase Set7/9 regulates p53 activity by interacting with Sirtuin 1 (SIRT1). Proceedings of the National Academy of Sciences of the United States of America 119 21245319
2010 Dynamic regulation of the PR-Set7 histone methyltransferase is required for normal cell cycle progression. Genes & development 110 20966048
2016 SETD7 Controls Intestinal Regeneration and Tumorigenesis by Regulating Wnt/β-Catenin and Hippo/YAP Signaling. Developmental cell 105 27046831
2010 Regulation of the androgen receptor by SET9-mediated methylation. Nucleic acids research 105 20959290
2009 SET7/9 mediated methylation of non-histone proteins in mammalian cells. Epigenetics 103 19684477
2012 The role of PR-Set7 in replication licensing depends on Suv4-20h. Genes & development 98 23152447
2011 The histone methyltransferase Set7/9 promotes myoblast differentiation and myofibril assembly. The Journal of cell biology 97 21859860
2009 Regulation of Set9-mediated H4K20 methylation by a PWWP domain protein. Molecular cell 93 19250904
2013 Methylation of SUV39H1 by SET7/9 results in heterochromatin relaxation and genome instability. Proceedings of the National Academy of Sciences of the United States of America 91 23509280
2008 Methyltransferase Set7/9 maintains transcription and euchromatin structure at islet-enriched genes. Diabetes 91 18984737
2015 Repression of hypoxia-inducible factor α signaling by Set7-mediated methylation. Nucleic acids research 90 25897119
2014 ER stress triggers MCP-1 expression through SET7/9-induced histone methylation in the kidneys of db/db mice. American journal of physiology. Renal physiology 85 24452638
2010 The Cellular lysine methyltransferase Set7/9-KMT7 binds HIV-1 TAR RNA, monomethylates the viral transactivator Tat, and enhances HIV transcription. Cell host & microbe 85 20227666
2012 Set9, NF-κB, and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells. Acta pharmacologica Sinica 82 23247593
2018 Biological processes and signal transduction pathways regulated by the protein methyltransferase SETD7 and their significance in cancer. Signal transduction and targeted therapy 81 30013796
2012 Methylation by Set9 modulates FoxO3 stability and transcriptional activity. Aging 81 22820736
2007 Mechanism of histone methylation catalyzed by protein lysine methyltransferase SET7/9 and origin of product specificity. Proceedings of the National Academy of Sciences of the United States of America 81 17517655
2011 The methyltransferase Set7/9 (Setd7) is dispensable for the p53-mediated DNA damage response in vivo. Molecular cell 73 21855806
2011 Lysine methylation and functional modulation of androgen receptor by Set9 methyltransferase. Molecular endocrinology (Baltimore, Md.) 72 21273441
2013 CRL1-FBXO11 promotes Cdt2 ubiquitylation and degradation and regulates Pr-Set7/Set8-mediated cellular migration. Molecular cell 69 23478445
2013 Transcriptional regulation by the Set7 lysine methyltransferase. Epigenetics 68 23478572
2016 SET9-Mediated Regulation of TGF-β Signaling Links Protein Methylation to Pulmonary Fibrosis. Cell reports 67 27292644
2015 SET7/9 regulates cancer cell proliferation by influencing β-catenin stability. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 67 26116705
2011 p53-dependent transcription and tumor suppression are not affected in Set7/9-deficient mice. Molecular cell 67 21855805
2008 PR-SET7 and SUV4-20H regulate H4 lysine-20 methylation at imprinting control regions in the mouse. EMBO reports 59 18724273
2018 Inhibition of Methyltransferase Setd7 Allows the In Vitro Expansion of Myogenic Stem Cells with Improved Therapeutic Potential. Cell stem cell 58 29395054
2019 Resveratrol induces p53 in colorectal cancer through SET7/9. Oncology letters 57 30881498
2016 Set7 mediated Gli3 methylation plays a positive role in the activation of Sonic Hedgehog pathway in mammals. eLife 57 27146893
2016 Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription. Journal of medicinal chemistry 55 27088648
2015 Discovery and Optimization of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Pharmacophore- and Docking-Based Virtual Screening. Journal of medicinal chemistry 53 26390175
2011 Genetic examination of SETD7 and SUV39H1/H2 methyltransferases and the risk of diabetes complications in patients with type 1 diabetes. Diabetes 53 21896933
2015 KMT Set7/9 affects genotoxic stress response via the Mdm2 axis. Oncotarget 50 26317544
2014 Set7/9 impacts COL2A1 expression through binding and repression of SirT1 histone deacetylation. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 50 23873758
2013 Crosstalk between SET7/9-dependent methylation and ARTD1-mediated ADP-ribosylation of histone H1.4. Epigenetics & chromatin 50 23289424
2017 The SETD8/PR-Set7 Methyltransferase Functions as a Barrier to Prevent Senescence-Associated Metabolic Remodeling. Cell reports 48 28249161
2015 Lysine Methyltransferase SETD7 (SET7/9) Regulates ROS Signaling through mitochondria and NFE2L2/ARE pathway. Scientific reports 47 26435321
2014 KMTase Set7/9 is a critical regulator of E2F1 activity upon genotoxic stress. Cell death and differentiation 47 25124555
2020 SET7/9 promotes multiple malignant processes in breast cancer development via RUNX2 activation and is negatively regulated by TRIM21. Cell death & disease 46 32102992
2011 A new regulator of the cell cycle: the PR-Set7 histone methyltransferase. Cell cycle (Georgetown, Tex.) 45 21200139
2016 Regulation of Transcription Factor Yin Yang 1 by SET7/9-mediated Lysine Methylation. Scientific reports 44 26902152
2018 Histone Methyltransferase Setd7 Regulates Nrf2 Signaling Pathway by Phenethyl Isothiocyanate and Ursolic Acid in Human Prostate Cancer Cells. Molecular nutrition & food research 43 29383876
2018 SETD7 Drives Cardiac Lineage Commitment through Stage-Specific Transcriptional Activation. Cell stem cell 43 29499155
2012 Direct methylation of FXR by Set7/9, a lysine methyltransferase, regulates the expression of FXR target genes. American journal of physiology. Gastrointestinal and liver physiology 43 22345554
2011 Coupling mitosis to DNA replication: the emerging role of the histone H4-lysine 20 methyltransferase PR-Set7. Trends in cell biology 43 21632252
2019 Methylation of UHRF1 by SET7 is essential for DNA double-strand break repair. Nucleic acids research 42 30357346
2018 SET7/9 promotes hepatocellular carcinoma progression through regulation of E2F1. Oncology reports 42 30106440
2016 The transcription factor GATA1 and the histone methyltransferase SET7 interact to promote VEGF-mediated angiogenesis and tumor growth and predict clinical outcome of breast cancer. Oncotarget 42 26848522
2016 Reduced expression of SET7/9, a histone mono-methyltransferase, is associated with gastric cancer progression. Oncotarget 41 26701885
2016 Histone H2AK119 and H2BK120 mono-ubiquitination modulate SET7/9 and SUV39H1 in type 1 diabetes-induced renal fibrosis. The Biochemical journal 39 27582499
2015 Transcriptional activity of the islet β cell factor Pdx1 is augmented by lysine methylation catalyzed by the methyltransferase Set7/9. The Journal of biological chemistry 39 25713082
2015 SCF(β-TRCP) promotes cell growth by targeting PR-Set7/Set8 for degradation. Nature communications 38 26666832
2013 SET7/9-dependent methylation of ARTD1 at K508 stimulates poly-ADP-ribose formation after oxidative stress. Open biology 38 24088713
2018 Inhibition of the H3K4 methyltransferase SET7/9 ameliorates peritoneal fibrosis. PloS one 34 29723250
2016 Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer cells and serves as an early-stage biomarker for predicting metastasis. Oncogene 34 27132511
2019 SETD7 mediates spinal microgliosis and neuropathic pain in a rat model of peripheral nerve injury. Brain, behavior, and immunity 33 31505256
2018 Setd7 and its contribution to Boron-induced bone regeneration in Boron-mesoporous bioactive glass scaffolds. Acta biomaterialia 33 29684621
2018 Histone-lysine N-methyltransferase SETD7 is a potential serum biomarker for colorectal cancer patients. EBioMedicine 31 30361067
2018 LSD1 demethylase and the methyl-binding protein PHF20L1 prevent SET7 methyltransferase-dependent proteolysis of the stem-cell protein SOX2. The Journal of biological chemistry 30 29358331
2018 Identification of Rpl29 as a major substrate of the lysine methyltransferase Set7/9. The Journal of biological chemistry 29 29959229
2021 lncRNA SNHG6 promotes hepatocellular carcinoma progression by interacting with HNRNPL/PTBP1 to facilitate SETD7/LZTFL1 mRNA destabilization. Cancer letters 28 34252487
2020 Downregulation of SETD7 promotes migration and invasion of lung cancer cells via JAK2/STAT3 pathway. International journal of molecular medicine 28 32323737
2018 SET-9 and SET-26 are H3K4me3 readers and play critical roles in germline development and longevity. eLife 28 29714684
2015 Functional regulation of hypoxia inducible factor-1α by SET9 lysine methyltransferase. Biochimica et biophysica acta 28 25637186
2013 MBTD1 is associated with Pr-Set7 to stabilize H4K20me1 in mouse oocyte meiotic maturation. Cell cycle (Georgetown, Tex.) 27 23475131
2023 Methylation of the Hippo effector YAP by the methyltransferase SETD7 drives myocardial ischaemic injury: a translational study. Cardiovascular research 26 35709329
2021 SETD7 regulates chondrocyte differentiation and glycolysis via the Hippo signaling pathway and HIF‑1α. International journal of molecular medicine 26 34617577
2017 Quercus infectoria inhibits Set7/NF-κB inflammatory pathway in macrophages exposed to a diabetic environment. Cytokine 26 28408068
2018 Inhibition of SETD7 protects cardiomyocytes against hypoxia/reoxygenation-induced injury through regulating Keap1/Nrf2 signaling. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 25 30119254
2015 SET7/9 Enzyme Regulates Cytokine-induced Expression of Inducible Nitric-oxide Synthase through Methylation of Lysine 4 at Histone 3 in the Islet β Cell. The Journal of biological chemistry 25 25995453
2016 SET7/9 inhibits oncogenic activities through regulation of Gli-1 expression in breast cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 24 26779630
2012 Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells. Biochimie 24 22709867
2021 IL-6 regulates the bone metabolism and inflammatory microenvironment in aging mice by inhibiting Setd7. Acta histochemica 23 33962150
2021 Loss of SPTBN1 Suppresses Autophagy Via SETD7-mediated YAP Methylation in Hepatocellular Carcinoma Initiation and Development. Cellular and molecular gastroenterology and hepatology 23 34737104
2020 Methylation of PLK1 by SET7/9 ensures accurate kinetochore-microtubule dynamics. Journal of molecular cell biology 23 31863092
2013 Structures of histone methyltransferase SET7/9 in complexes with adenosylmethionine derivatives. Acta crystallographica. Section D, Biological crystallography 23 23519668
2021 SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer's disease. Molecular neurodegeneration 22 34215303
2019 Regulation of SETD7 Methyltransferase by SENP3 Is Crucial for Sarcomere Organization and Cachexia. Cell reports 22 31141694
2014 Deep sequencing reveals novel Set7 networks. Cellular and molecular life sciences : CMLS 22 24875254
2023 SETD7 promotes metastasis of triple-negative breast cancer by YY1 lysine methylation. Biochimica et biophysica acta. Molecular basis of disease 21 37286143
2023 Trophoblast PR-SET7 dysfunction induces viral mimicry response and necroptosis associated with recurrent miscarriage. Proceedings of the National Academy of Sciences of the United States of America 21 37307441
2022 A Systematic Review to Define the Multi-Faceted Role of Lysine Methyltransferase SETD7 in Cancer. Cancers 21 35326563
2021 Histone lysine methyltransferase Pr-set7/SETD8 promotes neural stem cell reactivation. EMBO reports 21 33565211
2017 Opposite Effects of SET7/9 on Apoptosis of Human Acute Myeloid Leukemia Cells and Lung Cancer Cells. Journal of Cancer 21 28819408

Missed literature

Know a paper Affinage missed for SETD7? Flag it for the maintainers and the community.

No submissions yet.